Video

Considerations When Switching Therapy

A variety of immunotherapeutic agents with differing mechanisms of action are now available for the treatment of cancer. Richard W. Joseph, MD, discusses considerations regarding switching therapy in patients who experience disease progression.

While studies have been conducted of patients placed on an anti-PD-1 therapy following disease progression on ipilimumab, Dr Joseph remarks, there is a lack of data regarding treating patients with ipilimumab following disease progression on anti-PD-1 therapy.

Among other factors, treatment toxicities need to be considered before switching therapy, he adds. “In my personal experience, I tend to see that some of the side effects that patients had from ipilimumab will be reaggravated with anti-PD-1 [therapy]. I have also seen that not happen as well,” he comments.

Dr Joseph also briefly discusses the use of combination therapy (ipilimumab and anti-PD-1 therapy), and describes how the tolerability of combination therapy further complicates the making of treatment decisions.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Rachel Rohaidy, MD
Mansi Shah, MD
1 expert is featured in this series.
Miriam Freimer, MD
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Dr Pankit Vachhani
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo